By targeting both TGF‐β and PD‐L1 simultaneously with the STING agonist, even immune‐excluded or immune‐deserted tumors could benefit therapeutically.[76] To further improve the anti‐tumor response, NC NF‐kB inhibition, but not canonical NF‐kB inhibition promoted tumor regression in combination with irradiation[26] (Figure 4). The gene discussed is TGFB1; the disease is neoplasm.